Hyperferitinemie jako faktor spojený se špatnou prognózou u pacientů s COVID-19

Stáhnout PDF English version

Autoři: Nuhad Mohammed Al-Dulaimi ¹; Mahmood Jassim Mohammed ²; Saad T. Mutlk ³; Khalid F Al-Rawi ⁴; Hameed Hussein Ali ⁴; Bilal J. M. Aldahham ⁵; Faisal Al-Ani ⁶; Osamah Al-Ani ⁶; Yaqout A. Hamed ⁷; Aus T. Ali ^6,8
Působiště autorů: General Directorate of Education in Anbar, Ministry of Education, Al-anbar Province, Iraq ¹; Anbar Health Department, Ministry of Health, Al-anbar Province, Iraq ²; Department of Biology, College of Science, University of Anbar, Iraq ³; Department of Chemistry, College of Science, University of Anbar, Al-anbar Province, Iraq ⁴; Department of Applied Chemistry, College of Applied Sciences, University of Anbar, Al-anbar Province, Iraq ⁵; Faculty of Medicine, Odessa National Medical University Odessa ⁶; College of Pharmacy, University of Baghdad ⁷; Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa ⁸
Vyšlo v časopise: Čes. slov. Farm., 2023; 72, 223-232
Kategorie: Původní práce
doi: https://doi.org/10.5817/CSF2023-5-223

Souhrn

Od prosince 2019 se onemocněním COVID-19 nakazily stovky milionů lidí na celém světě, avšak závažné příznaky se objevily u 20 % nebo méně. Hlavním cílem této studie bylo posoudit vztah mezi závažností onemocnění COVID-19 a různými klinickými a laboratorními parametry. Do tohoto prospektivního souboru se ochotně zapojilo celkem 466 Arabů. Z celkového počtu mělo 297 osob (63,7 %) negativní test na COVID-19, a byly tedy zařazeny jako kontroly, zatímco 169 osob (36,3 %), u nichž byl test na COVID-19 pozitivní, bylo zařazeno jako případy. Z celkového počtu pacientů s COVID-19 mělo 127 pacientů (75,15 %) mírné příznaky a 42 pacientů (24,85 %) mělo závažné příznaky. Věkové rozmezí účastníků bylo 20 až 82 let. V porovnání s kontrolní skupinou byla závažnost onemocnění spojena s významně vyššími hladinami feritinu (P < 0,001). Závažnost onemocnění byla rovněž spojena s významným zvýšením C-reaktivního proteinu (P < 0,001), D-dimerů (P < 0,001), počtu bílých krvinek (WBC) (P < 0,01), IgM (P < 0,001) a granulocytů (P < 0,01). Kromě toho byly závažné příznaky COVID-19 v této studii spojeny s významným poklesem lymfocytů (P < 0,01). U pacientů s COVID-19, kteří se při přijetí prezentovali závažnými příznaky, došlo ke čtyřnásobnému zvýšení hladiny feritinu v séru. Ten byl spojen s významně vyššími hladinami CRP a D-dimerů. Hyperferitinémie spolu s vysokými koncentracemi CRP a D-dimerů tak mohou sloužit jako spolehlivé prediktory závažnosti onemocnění a špatné prognózy u Arabů s COVID-19.

Klíčová slova:

COVID-19 – feritin – mírné příznaky – závažné příznaky – špatná prognóza

Zdroje

Chen N., Zhou M., Dong X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223), 507–513.
Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395, 1054–1062.
Ghizlane E., Manal M., Abderrahim E., et al. Lymphopenia in Covid-19: A single center retrospective study of 589 cases. Ann. Med. Surg. 2021; 69, 102816.
Lee J., Park S. S., Kim Y. T., Lee D. G., Kim D. W. Lymphopenia as a Biological predictor of outcomes in COVID-19 patients: A Nationwide Cohort Study. Cancers (Basel) 2021; 13(3), 471.
Illg Z., Muller G., Mueller M., Nippert J., Allen B. Analysis of absolute lymphocytes count in patients with COVID-19. Am. J. Emerg. Med. 2021; 46, 16–19.
Petrilli C. M., Jones S. A., Yang J., et al. Factors associated with hospitalization and critical illness among 4,103 patients with Covid-19 disease in New York City. MedRxiv 2020.
Vitte J., Diallo A. B., Boumaza A., Lopez A., Michael M., Allardet-Servent J. A granulocytes signature identifies COVID-19 and it is severity. J. Infect. Dis. 2020; 222(12), 1985–1996.
Zhu B., Feng X., Jiang C., et al. Correlation between white blood cell count at admission and mortality in COVID-19 patients: a retrospective study. BMC infect. Dis. 2021; 21, 574.
Varikasuvu S. R., Varshney S., Dutt N., et al. D-dimer, disease severity, and deaths (3D-study) in patients with COVID-19: a systematic review and meta-analysis of 100 studies. Sci. Rep. 2021; 11, 21888.
Zhan H., Chen H., Liu C., et al. Diagnostic value of D-dimer in COVID-19: A meta-analysis and meta-regression. Clin Appl Thromb. Hemost. 2021; 27, 1–10.
Kernan K. F., Carcillo J. A. Hyperferritinemia and inflammation. Int. Immunol. 2017; 29(9), 401–409.
Ogilvie C., Fitzsimons K., Fitzsimons E. Serum ferritin values in primary care: are high values overlooked? J. Clin. Pathol. 2020; 63, 1124–1126.
Sandnes M., Ulvik R. J., Vorland M., Reikvam H. Hyperferritinemia-A clinical overview. J. Clin. Med. 2021; 10(9), 2008.
Beaton M. D., Adams P. C. Treatment of hyperferritinemia. Ann. Hepatol. 2012; 11(3), 294–300.
Carubbi F., Salvati L., Alunno A., et al. ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. Sci. Rep. 2021; 11, 4863.
Rosario C., Zandman-Goddard G., Meyron-Holtz E. G., D’Cruz D. P., Shoenfeld Y. The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013; 11(2013), 185.
Senjo H., Higuchi T., Okada S., Takahashi O. Hyperferritinemia: causes and significance in a general hospital. Hematology 2018; 23(10), 817–822.
Abbaspour N., Hurrell R., Kelishadi R. Review on iron and its importance for human health. Research J. Med. Sci. 2014; 19(2), 164–174.
Abul Y., Leeder C., Gravenstein S. Epidemiology and clinical presentation of COVID-19 in older adults. Infect. Dis. Clin. North Am. 2023; 37(1), 1–26.
Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11), 1061–1069.
Nanda A., Vura N.V.R. K, Gravenstein S. COVID-19 in older adults. Aging Clin. Exp. Res. 2020; 32, 1199–1202.
Powell T., Bellin E., Ehrlich A. R. Older adults and Covid-19: The most vulnerable, the hardest hit. Hastings Center Report 2020; 50(3), 61–63.
Paget J., Spreeuwenberg P., Charu V., et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J. Glob. Health 2019; 9(2), 020421.
Feinkohl, I., Janke, J., Hadzidiakos, D., et al. Associations of the metabolic syndrome and its components with cognitive impairment in older adults. BMC Geriatr. 2019; 19, 77.
Assuncao N., Sudo F. K, Drummond C., de Felice F. G., Mattos P. Metabolic syndrome and cognitive decline in the elderly: A systematic review. PLoS One 2018; 13(3), e0194990.
Ali A. T., Al-ani O., Al-ani F. Epidemiology and risk factors for ovarian cancer. Menopause Rev. 2023; 22(2), 93–104.
Ali A. T. Risk factors for endometrial cancer. Ces. Gynekol. 2013; 78(5), 448–459.
Ali A. T. Towards prevention of ovarian cancer. Current Cancer Drug Targets 2018; 18(6), 522–537.
Ali A. T. Can we prevent ovarian cancer? Ces. Gynekol. 2020; 85(1), 49–58.
Ali A.T., Al-Ani F., Al-Ani O. Childhood obesity: causes, consequences, and prevention. Čes. slov. Farm. 2023; 72(1), 21–36.
Nour T. Y., ALTINTAŞ K. H. Effect of the COVID-19 pandemic on obesity and its risk factors: a systematic review. BMC Public Health 2023; 23, 1018.
Ho J. S. Y., Fernando D. I., Chan M. Y., Sia C. H. Obesity in COVID-19: A Systematic review and meta-analysis. Ann. Acad. Med. Singap. 2020; 49(12), 996–1008.
Dujardin R. W. G., Hilderink B. N., Haksteen W. E., et al. Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients. Thromb. Res. 2020; 196, 308–312.
Moore jr. C., Ormseth M., Fuchs H. Causes and significance of markedly elevated serum ferritin levels in and academic medical center. J. Clin. Rheumatol. 2013; 19(6), 324–328.
Acanfora D., Scicchitano P., Carone M., et al. Relative lymphocyte count as an indicator of 3-year mortality in elderly people with severe COPD. BMC Pulm. Med. 2018; 18, 116.
Tavakolpour S., Rakhshandehroo T., Wei E. X., Rashidian M. Lymphopenia during the COVID-19 infection: What it shows and what can be learned. Immuno. Lett 2020; 225, 31–32.
Acanfora D., Gheorghiade M., Trojano L., et al. Relative lymphocyte count: a prognostic indicator of mortality in elderly patients with congestive heart failure. Am. Heart J. 2001; 142, 167–173.
Nunez J., Sanchis J., Bodi V., et al. Relationship between low lymphocyte count and major cardiac events in patients with acute chest pain, a non-diagnostic electrodiagram and normal tropnin levels. Atherosclerosis 2009; 206, 251–257.
Al-Rawi K. F., Ali H. H., Guma M. A., et al. Relationship between IL-2, IL-17 concentrations, and serum creatinine levels in men with chronic kidney diseases. Rep. Biochem. Mol. Biol. 2022; 10(4), 664–674.
Ali H. H., Al-Rawi K., Khalaf Y., et al. Serum caveolin-1 level is inversely associated with serum vaspin, visfatin, and HbA1c in newly diagnosed men with type-2 diabetes. Rep. Biochem. Mol. Biol. 2022; 11(2), 299–309.